A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
A phase 1/2 trial of ARV-806 in advanced solid tumours, run by Arvinas Inc., active and no longer recruiting.
Overview
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation is a phase 1/2 interventional study registered as NCT07023731 by Arvinas Inc., with 76 participants enrolled, started 2025-05-29 and due to reach its primary completion in 2026-11-30. Interventions recorded: ARV-806.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
Shares Arvinas, Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialInvestigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPlasmodium Immunotherapy for Advanced Malignant Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialFirst-in-Human Study of ICT01 in Patients With Advanced Cancer
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialPhase 1/2a Study of MPB-1734 in Patients With Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialA Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
- TrialAuger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.